Medifocus

Medifocus Inc. is a public medical technology company with a mission to improve standards of care through its proprietary focused heat platforms. Its strategy leverages a revenue-generating, FDA-approved device for BPH (Prolieve®) to fund the clinical development of its late-stage Adaptive Phased Array (APA-1000) system for breast cancer. The company has established a robust intellectual property portfolio with approximately 100 patents and has secured regulatory approvals to initiate a pivotal Phase III trial for its oncology asset.

Two proprietary focused heat platforms: 1) Endo-thermotherapy for combined heat and mechanical dilation, and 2) Adaptive Phased Array (APA) microwave focusing for precise, deep-tissue tumor heating and ablation.

In BPH, Prolieve competes against established office-based therapies like UroLift and Rezūm. In breast cancer, the APA-1000's focused hyperthermia is a niche approach, competing for adoption against standard-of-care treatments and other ablation technologies; its deep-tissue focusing capability is a key differentiator.